Appeal No. 1998-0350
Application No. 08/453,937
(LACI)1 was known to interfere with the extrinsic blood coagulation pathway. Id.,
page 2. Heparin was also known in the prior art to be an anticoagulant. Id.,
page 1. Anticoagulants are used in treating thrombotic diseases such as
disseminated intravascular coagulation. Id., page 3. The specification discloses
pharmaceutical compositions comprising heparin or another sulfated
polysaccharide and LACI.
The specification states that the combination of LACI and a sulfated
polysaccharide such as heparin produces a synergistic anticoagulant effect in
whole blood plasma. Page 3. The specification presents several working
examples showing the effects of heparin and LACI on extrinsic pathway
coagulation, both alone and in combination. See pages 16-19 and Figure 4. The
evidence of record also includes two declarations under 37 CFR § 1.132 by
Appellant Tze-Chein Wun and one declaration under 37 CFR § 1.132 by George
J. Broze, Jr. See Paper Nos. 9 and 13 in parent application 08/166,186, and
Paper No. 5 in the instant application, respectively.
Discussion
1. Procedural History
According to Appellant, the instant application is a continuation-in-part of
application 08/166,186, which is a continuation of application 07/573,083. The
‘083 grandparent application was the subject of a previous appeal to this Board.
The claims in the ‘083 grandparent application were rejected as anticipated or
1 LACI is also known in the art as tissue factor inhibitor (TFI) and extrinsic pathway inhibitor (EPI).
Specification, page 2.
3
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 Next
Last modified: November 3, 2007